NGAL (5G5): sc-57517



The Power to Question

BACKGROUND

In addition to the monomeric mammalian progelatinase, two additional forms of progelatinase have been identified. The shorter of these additional forms is a covalently linked, disulfide-bridged protein that heterodimerizes with a short protein; an $\alpha_2\text{-}\text{Microglobulin-related}$ protein known as neutrophil gelatinase-associated lipocalin (NGAL), which is moderately expressed in breast and lung tissues. NGAL belongs to the lipocalin family and has a high degree of similarity with rat $\alpha_2\text{-}\text{Microglobulin-related}$ protein and mouse protein 24p3. NGAL is able to bind a derivative of the bacterial chemotactic peptide, suggesting that it has important immuno-modulatory functions. NGAL has been described as an inflammatory protein; it is released into the circulation as a result of the inflammatory activation of leukocytes initiated by the extra-corporeal circulation. In addition, NGAL synthesis is induced in epithelial cells in inflammatory and neoplastic colorectal diseases. In conclusion, NGAL may serve as a scavenger of bacterial products to function in the anti-inflammatory process.

REFERENCES

- 1. Triebel, S., et al. 1992. A 25 kDa α_2 -Microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett. 314: 386-388.
- Kjeldsen, L., et al. 1993. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268: 10425-10432.
- 3. Bundgaard, J.R., et al. 1994. Molecular cloning and expression of a cDNA encoding NGAL: a lipocalin expressed in human neutrophils. Biochem. Biophys. Res. Commun. 202: 1468-1475.
- Nielsen, B.S., et al. 1996. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38: 414-420.
- 5. Stoesz, S.P., et al. 1998. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int. J. Cancer 79: 565-572.
- Jonsson, P., et al. 1999. Extracorporeal circulation causes release of neutrophil gelatinase-associated lipocalin (NGAL). Mediators Inflamm. 8: 169-171.

CHROMOSOMAL LOCATION

Genetic locus: LCN2 (human) mapping to 9q34.11.

SOURCE

NGAL (5G5) is a mouse monoclonal antibody raised against full length native NGAL isolated from neutrophils of human origin.

PRODUCT

Each vial contains 100 $\mu g \ lgG_1$ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

NGAL (5G5) is recommended for detection of native and denatured forms of NGAL of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for NGAL siRNA (h): sc-43969, NGAL shRNA Plasmid (h): sc-43969-SH and NGAL shRNA (h) Lentiviral Particles: sc-43969-V.

Molecular Weight of NGAL: 23 kDa.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

SELECT PRODUCT CITATIONS

- 1. Yano, S., et al. 2008. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J. Cell. Physiol. 214: 1-13.
- Krysan, K., et al. 2013. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am. J. Transl. Res. 5: 481-496.

RESEARCH USE

For research use only, not for use in diagnostic procedures

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com